Conivaptan: potential therapeutic implications in heart failure.
Conivaptan, a dual vasopressin receptor antagonist, is a member of an emerging class of medications for the treatment of euvolemic hyponatremia. These agents induce a free-water diuresis as compared to the natriuretic effect of loop diuretics and make them an intriguing prospect for the treatment of congestive heart failure. Article also includes recent patents on this topic.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Stephen Y
SY
Chen
Zuheir
Z
Abrahams
George G
GG
Sokos
Wilfried
W
Mullens
Robert
R
Hobbs
David O
DO
Taylor
Gonzalo V
GV
Gonzalez-Stawinski
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D010330:Patents as Topic; D016896:Treatment Outcome; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D002317:Cardiovascular Agents; D004232:Diuretics; D006727:Hormone Antagonists; C106389:conivaptan